The collaboration will focus on cytometry by time-of-flight (CyTOF)-based research performed in the Karolinska Institutet’s Department of Women’s and Children’s Health.
Imaging mass cytometry enabled the researchers to view not only the structure of the tissue, but also the interplay between infected cells and the immune system in COVID-19 patients...
Mass cytometry technology from Fluidigm is being used in a prospective observational cohort surveillance study of up to 2000 adult participants hospitalized with COVID-19.
The integration of novel laser ablation and mass cytometry enables spatial resolution of single-cell phenotypes, promising a new advance for cancer diagnostics and therapy.
Buyer's Guide Listing Information
Click here for listing information and directions on how to add or update your company.
Request More Information From Fluidigm Corporation